Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis

Giulio Disanto; Rosaria Sacco; Enos Bernasconi; Gladys Martinetti; Franco Keller; Claudio Gobbi; Chiara Zecca

doi:10.1001/jamaneurol.2021.3609

Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis

JAMA Neurol. 2021 Dec 1;78(12):1529-1531. doi: 10.1001/jamaneurol.2021.3609.

Authors

Giulio Disanto¹, Rosaria Sacco¹, Enos Bernasconi^{2

3

4}, Gladys Martinetti⁵, Franco Keller⁵, Claudio Gobbi^{1

3}, Chiara Zecca^{1

3}

Affiliations

¹ Multiple Sclerosis Center, Department of Neurology, Neurocenter of Southern Switzerland (NSI), Regional Hospital of Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.
² Department of Medicine, Regional Hospital of Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.
³ Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
⁴ University of Geneva, Geneva, Switzerland.
⁵ Institute of Laboratory Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Abstract

This cohort study investigates the humoral response to 2 SARS-CoV-2 messenger RNA vaccines in patients with multiple sclerosis treated with fingolimod and ocrelizumab.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antigens, CD20 / immunology*
COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Female
Humans
Immunity, Humoral / immunology*
Immunosuppressive Agents
Lymphocyte Count
Male
Middle Aged
Multiple Sclerosis / immunology*

Substances

Antibodies, Monoclonal
Antigens, CD20
COVID-19 Vaccines
Immunosuppressive Agents